Clinical trial
AMBroxol Therapy for ALS (AMBALS) Trial: a Double-blind, Randomised, Placebo-controlled Phase 2 Clinical Trial of Ambroxol for ALS
NCT05959850 is registered in ClinicalTrials.gov with The Florey Institute of Neuroscience and Mental Health as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- AMBroxol Therapy for ALS (AMBALS) Trial: a Double-blind, Randomised, Placebo-controlled Phase 2 Clinical Trial of Ambroxol for ALS
- Lead sponsor
- The Florey Institute of Neuroscience and Mental Health
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- June 13, 2023
- Completion date
- December 31, 2024
- Enrollment
- 50 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.